Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients

Table 2 Univariable and multivariable analysis regarding two-year hepatocellular carcinoma disease-free survival in the estimation cohort

Covariate	Non-HCC (n = 54)	HCC (n = 8)	Univariable analysis HR (95%CI; P value)	Multivariable analysis HR (95%CI; P value)
Gender (Male)	75.9% (41/54)	62.5% (5/8)	0.571 (0.137-2.392; 0.444)
mean age (yr)	55.96 ± 10.82	54.5 ± 8.5	0.987 (0.924-1.055; 0.706)
Etiology (alcohol/HCV/HBV/other)	25/17/10/2	1/7/0/0	1.075 (0.481-2.405; 0.859)
Child-Pugh (A/B/C)	35/14/5	5/3/0	0.922 (0.290-2.935; 0.891)
AST (IU/mL)	63.94 ± 42.21	107.29 ± 69.83	1.013 (1.002-1.024; 0.021)
ALT (IU/mL)	58.86 ± 55.48	77.29 ± 62.52	1.004 (0.993-1.015; 0.452)
Tot. Bilirubin (mg/dL)	1.97 ± 3.05	1.75 ± 1.02	0.983 (0.734-1.316; 0.906)
Creatinine (mg/dL)	0.83 ± 0.20	2.04 ± 3.44	1.363 (1.055-1762; 0.018)	1.564 (1.151-2.124; 0.004)
Platelets (× 109/mL)	102.25 ± 43.28	88.00 ± 42.89	0.992 (0.974-1.010; 0.387)
Albumin (mg/dL)	3833 ± 625	3642 ± 525	1.000 (0.998-1.001; 0.394)
AFP (ng/mL)	7.80 ± 9.25	40.38 ± 62.71	1.024 (1.010-1.038; 0.001)	1.028 (1.009-1.046; 0.003)
SCCA-IgM (AU/mL)	136.83 ± 163.44	608.75 ± 1093.53	1.001 (1.000-1.002; 0.004)	1.001 (1.000-1.002; 0.003)

Cox proportional hazards model was used to estimate the hazard ratios and CIs in the multivariable analysis. Data are numbers of patients (%) or mean ± SD. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alfa-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen and its immune complexes; Child-Pugh score: The Child–Turcotte–Pugh score or Child Criteria; HCC: Hepatocellular carcinoma; HR: Hazard ratio.